Increase of Phosphoribosylpyrophosphate Levels in Cultured L1210 Leukemia Cells Exposed to Methotrexate

  • J. M. Buesa
  • A. Leyva
  • H. M. Pinedo
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 122B)


MTX is a folic acid analog that binds to the enzyme dihydro-folate reductase and inhibits its activity depleting the cells of reduced folates. It blocks the synthesis of dTMP from dUMP and de novo purine biosynthesis by decreasing the availability of reduced folates1. MTX effects on cell metabolism can be reversed not only by folinic acid (5-formyltetrahydrofolic acid) but also by either TdR alone or TdR plus a purine base or nucleoside2–6 which provide for nucleotide synthesis through salvage pathways. Purine bases are converted to nucleotides by phosphoribosyltransferases in the presence of PRPP as the phosphoribosyl donor and TdR phosphorylation to dTMP by TdR kinase requires ATP. MTX has been demonstrated to cause a rapid decrease of intracellular ATP levels, which could restrict the cellular utilization of TdR7 . The purpose of our study was to evaluate the effect of MTX on the intracellular levels of PRPP in order to assess the availability of PRPP for purine salvage during MTX treatment.


Folinic Acid Purine Base Ehrlich Ascites Carcinoma Cell Purine Biosynthesis L12l0 Cell 















Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    J. R. Bertino, Folate Antagonists, in: “Antineoplastic Agents Part II,” A. C. Sartorelli and D. G. Johns, ed., Springer-Verlag, Berlin (1975).Google Scholar
  2. 2.
    J. Borsa, and G. F. Whitmore, Cell Killing Studies on the Mode of Action of Methotrexate on L-cells in Vitro, Cancer Res. 29:737 (1969).PubMedGoogle Scholar
  3. 3.
    M. H. N. Tattersall, R. C. Jackson, S. T. M. Jackson, and K. R. Harrap, Factors Determining Cell Sensitivity of Methotrexate: Studies of Folate and Deoxyribonucleoside Triphosphate Pools in Five Mammalian Cell lines, Eur. J. Cancer 10:819 (1974).PubMedCrossRefGoogle Scholar
  4. 4.
    W. M. Hryniuk, The Mechanism of Action of Methotrexate in Cultured L5178Y Leukemia Cells, Cancer Res. 35:1085 (1975).PubMedGoogle Scholar
  5. 5.
    H. M. Pinedo, D. S. Zaharko, J. M. Bull, and B. A. Chabner, The Reversal of Methotrexate Cytotoxicity to Mouse Bone Marrow Cells by Leucovorin and Nucleosides, Cancer Res. 36:4418 (1976).PubMedGoogle Scholar
  6. 6.
    A. Leyva, L. van de Grint, and H. M. Pinedo, Reversal of Methotrexate Toxicity to Mouse Bone Marrow and L1210 Leukemia Cells Grown in Vitro, in: “Clinical Pharmacology of Antineoplastic Drugs”, H. M. Pinedo, ed., Elsevier/ North Holland Biomedical Press, Amsterdam (1978).Google Scholar
  7. 7.
    W. M. Hryniuk, L. W. Brox, J. F. Henderson, and T. Tamaoki, Consequences of Methotrexate Inhibition of Purine Biosynthesis in L5178Y Cells, Cancer Res. 35:1427 (1975).PubMedGoogle Scholar
  8. 8.
    T. Hisata, An Accurate Method for Estimating 5-Phosphoribosyl-1-pyrophosphate in Animal Tissues with the use of Acid Extraction, Anal. Biochem. 68:448 (1975).PubMedCrossRefGoogle Scholar
  9. 9.
    I. H. Fox, and W. N. Kelley, Human Phosphoribosylpyrophosphate Synthetase, Distribution, Purification and Properties, J. Biol. Chem. 246:5739 (1971).PubMedGoogle Scholar
  10. 10.
    E. Kaminskas, and A. C. Nussey, Effects of Methotrexate and of Environmental Factors on Glygolysis and Metabolic Energy State in Cultured Ehrlich Ascites Carcinoma Cells, Cancer Res. 38:2989 (1978).PubMedGoogle Scholar
  11. 11.
    E. Cadman, C. Benz, and R. Heimer, Enhanced 5-Fluorouracil Nucleotide Formation Following Methotrexate is the Consequence of Increased Intracellular Phosphoribosylpyrophosphate. Proc. AACR. 20:258 (1979).Google Scholar
  12. 12.
    A. Leyva, J. Schomagel, H. M. Pinedo, High Performance Liquid Chromatography of Plasma Pyrimidines and Purines and its Application in Cancer Chemotherapy (See this volume).Google Scholar
  13. 13.
    S. B. Howell, W. D. Ensminger, A. Krishan, and E. Frei III, Thymidine Rescue of High-Dose Methotrexate in Humans, Cancer Res. 38:325 (1978).PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1980

Authors and Affiliations

  • J. M. Buesa
    • 1
    • 2
    • 3
  • A. Leyva
    • 1
    • 2
    • 3
  • H. M. Pinedo
    • 1
    • 2
    • 3
  1. 1.Section of ChemotherapyGeneral Hospital of AsturiasOviedoSpain (J.M.B.)
  2. 2.Section of Experimental ChemotherapyAntoni van Leeuwenhoek InstituteAmsterdamThe Netherlands
  3. 3.(J.M.B., A.L., H.M.P.) and Department of OncologyFree University Hospital (A.L., H.M.P.)AmsterdamThe Netherlands

Personalised recommendations